Thomas Wegener

581 total citations
23 papers, 475 citations indexed

About

Thomas Wegener is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Surgery. According to data from OpenAlex, Thomas Wegener has authored 23 papers receiving a total of 475 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 6 papers in Physiology and 5 papers in Surgery. Recurrent topics in Thomas Wegener's work include Inhalation and Respiratory Drug Delivery (8 papers), Asthma and respiratory diseases (6 papers) and Blood properties and coagulation (3 papers). Thomas Wegener is often cited by papers focused on Inhalation and Respiratory Drug Delivery (8 papers), Asthma and respiratory diseases (6 papers) and Blood properties and coagulation (3 papers). Thomas Wegener collaborates with scholars based in Sweden, Denmark and Singapore. Thomas Wegener's co-authors include Hans Hedenström, Hildebert Wagner, B Melander, Ingemar Selinus, Einar Skarfors, Hans Lithell, Morgan Andersson, Marieann Högman, Margareta Emtner and Pekka Meriläinen and has published in prestigious journals such as CHEST Journal, Diabetologia and Allergy.

In The Last Decade

Thomas Wegener

23 papers receiving 440 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas Wegener Sweden 10 301 266 52 38 30 23 475
B. J. Freedman United Kingdom 11 213 0.7× 189 0.7× 16 0.3× 30 0.8× 69 2.3× 19 455
Wilmore Dw United States 13 260 0.9× 77 0.3× 41 0.8× 43 1.1× 138 4.6× 24 608
John Keighley United States 10 130 0.4× 290 1.1× 25 0.5× 80 2.1× 117 3.9× 19 599
T Remer Germany 7 447 1.5× 81 0.3× 72 1.4× 168 4.4× 24 0.8× 10 871
D Boda Hungary 12 48 0.2× 139 0.5× 12 0.2× 102 2.7× 64 2.1× 59 511
M Schulte United States 6 143 0.5× 106 0.4× 25 0.5× 21 0.6× 40 1.3× 7 383
Burton M. Cohen United States 12 102 0.3× 124 0.5× 11 0.2× 37 1.0× 62 2.1× 38 383
Brian M. Morrissey United States 16 253 0.8× 495 1.9× 11 0.2× 108 2.8× 92 3.1× 34 789
Margaret A. Allman Australia 8 162 0.5× 52 0.2× 32 0.6× 16 0.4× 48 1.6× 11 371
Valerie Langberg United States 7 106 0.4× 53 0.2× 27 0.5× 47 1.2× 67 2.2× 8 508

Countries citing papers authored by Thomas Wegener

Since Specialization
Citations

This map shows the geographic impact of Thomas Wegener's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Wegener with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Wegener more than expected).

Fields of papers citing papers by Thomas Wegener

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Wegener. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Wegener. The network helps show where Thomas Wegener may publish in the future.

Co-authorship network of co-authors of Thomas Wegener

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Wegener. A scholar is included among the top collaborators of Thomas Wegener based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Wegener. Thomas Wegener is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wegener, Thomas & Hildebert Wagner. (2006). The active components and the pharmacological multi-target principle of STW 5 (Iberogast®). Phytomedicine. 13. 20–35. 44 indexed citations
2.
Högman, Marieann, Thomas Wegener, Margareta Emtner, et al.. (2002). Extended NO analysis applied to patients with COPD, allergic asthma and allergic rhinitis. Respiratory Medicine. 96(1). 24–30. 113 indexed citations
3.
O’Connor, Brian, et al.. (2001). Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator. Annals of Allergy Asthma & Immunology. 86(4). 397–404. 42 indexed citations
4.
Personne, Mark, Lars Rombo, Håkan Sandler, & Thomas Wegener. (1999). [Serious effects of chloroquine overdose. Prescribe the smallest possible dosage-packages and inform about the risks].. PubMed. 96(46). 5086–7. 3 indexed citations
5.
Steffensen, Ida, et al.. (1995). *Inhaled formoterol dry powder in the treatment of patients with reversible obstructive airway disease. Allergy. 50(8). 657–663. 50 indexed citations
6.
Sandler, Håkan, et al.. (1994). Effect of Ibuprofen on Thrombin-induced Pulmonary Edema in the Rat. Pulmonary Pharmacology. 7(6). 393–399. 3 indexed citations
7.
Stålenheim, Gunnemar, Thomas Wegener, Bo Lundbäck, et al.. (1994). Efficacy and Tolerance of a 12-Week Treatment with Inhaled Formoterol in Patients with Reversible Obstructive Lung Disease. Respiration. 61(6). 305–309. 9 indexed citations
8.
Wegener, Thomas, Hans Hedenström, & B Melander. (1992). Rapid Onset of Action of Inhaled Formoterol in Asthmatic Patients. CHEST Journal. 102(2). 535–538. 47 indexed citations
9.
Hedenström, Hans, Thomas Wegener, G Boman, L. Wåhlander, & B Melander. (1992). Effect of inhaled formoterol versus terbutaline on respiratory function in moderate bronchial asthma. Allergy. 47(2). 158–163. 12 indexed citations
10.
Wegener, Thomas, et al.. (1988). N-Acetylcysteine in Paraquat Toxicity: Toxicological and Histological Evaluation in Rats. Upsala Journal of Medical Sciences. 93(1). 81–89. 16 indexed citations
11.
Skarfors, Einar, Thomas Wegener, Hans Lithell, & Ingemar Selinus. (1987). Physical training as treatment for Type 2 (non-insulin-dependent) diabetes in elderly men. A feasibility study over 2 years. Diabetologia. 30(12). 930–933. 73 indexed citations
12.
Wegener, Thomas, et al.. (1987). Effect of ipratropium bromide aerosol on respiratory function in patients under ventilator treatment. Acta Anaesthesiologica Scandinavica. 31(7). 652–654. 13 indexed citations
13.
Wegener, Thomas & Hans Hedenström. (1987). Effect of Nebulized Ipratropium Bromide on Lung Function in Nonallergic Bronchial Asthma. Respiration. 52(1). 1–6. 5 indexed citations
14.
Wegener, Thomas, Bo Sandhagen, & Tom Saldeen. (1987). Effect of N-acetylcysteine on pulmonary damage due to microembolism in the rat.. PubMed. 70(4). 205–12. 13 indexed citations
15.
Wegener, Thomas, et al.. (1986). Computed Chest Tomography in Rats with Pulmonary Damage Due to Microembolism. Acta Radiologica Diagnosis. 27(6). 723–728. 5 indexed citations
16.
Wegener, Thomas, Rolf Wallin, & Tom Saldeen. (1986). Effect of N-Acetylcysteine on Fibrin Deposition in the Rat Lung due to Intravascular Coagulation. Upsala Journal of Medical Sciences. 91(1). 45–52. 4 indexed citations
17.
Sandhagen, Bo & Thomas Wegener. (1985). Blood Viscosity and Finger Systolic Pressure in Primary and Traumatic Vasospastic Disease. Upsala Journal of Medical Sciences. 90(1). 55–59. 7 indexed citations
18.
Wegenius, G., et al.. (1985). Videodensitometry in Rats with Pulmonary Damage Due to Microembolism. Acta Radiologica Diagnosis. 26(6). 785–788. 2 indexed citations
19.
Wegener, Thomas, G. Wegenius, Tom Saldeen, & Uno Erikson. (1983). Serial Pulmonary Angiography in Rats with Pulmonary Damage Due to Intravascular Coagulation. Acta Radiologica Diagnosis. 24(6). 449–457. 3 indexed citations
20.
Wegener, Thomas, Lars Bagge, Olle Lindquist, & Tom Saldeen. (1975). Induction of fibrinolysis inhibition in the rat and the dog. Forensic Science. 6(3). 260–260. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by B. J. Freedman Breakdown of academic impact, for papers by Wilmore Dw Breakdown of academic impact, for papers by John Keighley Breakdown of academic impact, for papers by T Remer Breakdown of academic impact, for papers by D Boda Breakdown of academic impact, for papers by M Schulte Breakdown of academic impact, for papers by Burton M. Cohen Breakdown of academic impact, for papers by Brian M. Morrissey Breakdown of academic impact, for papers by Margaret A. Allman Breakdown of academic impact, for papers by Valerie Langberg
Rankless by CCL
2026